Patent ID: 11865175
Assignee: CEDARS-SINAI MEDICAL CENTER
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for post transplant treatment or inhibition of antibody-mediated rejection (ABMR) in a subject who has received an organ transplantation, the method consisting of:
administering a therapeutically effective amount of intravenous immunoglobulin (IVIG) and an anti-CD20 agent in one or more pharmaceutical compositions to the subject who has received an organ transplantation, or
administering a therapeutically effective amount of the IVIG, the anti-CD20 agent, and one or more of antithymocyte globulin, alemtuzumab, a glucocorticoid, mycophenolate mofetil, tacrolimus, and antibiotics, in one or more pharmaceutical compositions to the subject who has received the organ transplantation,
wherein the anti-CD20 agent comprises rituximab, ofatumumab, obinutuzumab, tositumomab, ocaratuzumab, ocrelizumab, TRU-015, IMMU-106, or a combination thereof; and
wherein, if the subject did not receive rituximab before the transplantation, the IVIG and the anti-CD20 agent are administered only between 3 days and 10 days after the transplantation, or the IVIG is administered only between 7 days and 14 days after the transplantation and the anti-CD20 agent is administered only between 14 days and 21 days after the transplantation, or
wherein, if the subject received the rituximab before the transplantation, the IVIG and the anti-CD20 agent are administered only between 3 days and 10 days after the transplantation.